AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.

AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's guidance ...

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...

AbbVie (NYSE:ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing its ...

AbbVie’s solid stock performance is driven by rising investor optimism as the company has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, which once generated ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raising ...